H-Aib-OMe*HCl

H-Aib-OMe*HCl is the hydrochloride salt of the methyl ester of alanine-α-aminoisobutyric acid (Aib), where the amino group is present as an acid-stabilized salt and the carboxyl functionality is masked as a methyl ester. The Aib side chain is characterized by two methyl substituents that increase steric bulk and conformational bias, while the α-chiral center provides stereochemical control for downstream peptide construction. The methyl ester and the protonated amine form a protected amino acid ester motif that can participate in peptide coupling after appropriate neutralization or activation. The salt form improves handling of the amino ester in synthesis workflows and supports its use as a chiral intermediate for generating Aib-containing peptides, peptidomimetics, and conformationally constrained analogs.

1. Peptide Synthesis

H-Aib-OMe*HCl is applied in peptide coupling workflows where an Aib-containing amino acid ester serves as a stereodefined building block for assembling short peptides and constrained sequences. The protonated amino group and the methyl ester functionality align with standard protected amino acid chemistry, enabling conversion to activated derivatives for amide bond formation at the α-position while preserving the conformationally biased Aib side chain. Neutralization and ester activation strategies can be used to integrate the Aib residue into peptide chains, supporting N-to-C sequential assembly and C-terminal ester or derivative formation depending on the coupling plan. Downstream, Aib-rich peptides prepared from this intermediate can be used as reference scaffolds in peptide chemistry and structure-function investigations that rely on predictable backbone conformations.

2. Peptidomimetics And SAR

H-Aib-OMe*HCl supports peptidomimetic construction for structure-activity relationship studies where Aib residues are incorporated to modulate secondary structure propensity and proteolytic stability trends. The sterically hindered Aib side chain and the α-chiral center enable systematic variation of conformational constraints across analog series, while the methyl ester provides a handle for further functional group transformation into alternative C-terminal motifs. Ester-to-acid, ester-to-amide, or ester to other derivatized termini can be applied after peptide assembly to generate libraries of analogs suitable for SAR mapping and comparative physicochemical characterization. The product thus functions as a chiral amino acid intermediate for building constrained peptide-like scaffolds used in medicinal chemistry research and molecular design campaigns.

3. Chiral Amino Acid Intermediate

H-Aib-OMe*HCl is utilized as a chiral amino acid intermediate in asymmetric synthesis planning and downstream derivatization routes that require a defined Aib stereocenter. The hydrochloride salt form stabilizes the amino ester during handling and can be compatible with process steps that generate activated coupling partners, including conversion to acylating agents or incorporation into protected amino acid derivatives. The methyl ester protects the carboxyl group during early-stage functionalization, allowing selective transformations on the side chain or on the terminal functionality after the chiral center is established. The resulting Aib-containing intermediates can be employed to prepare stereochemically controlled peptide building blocks, conformationally biased fragments, and synthesis-ready units for fine chemical manufacturing.

4. Pharmaceutical Intermediate Preparation

H-Aib-OMe*HCl is relevant to pharmaceutical intermediate preparation where Aib-containing fragments are used to generate peptide-like building blocks for process chemistry and scale-up of constrained analogs. The amino acid ester format and the acid salt form support manufacturing-friendly handling of a defined stereochemical unit, while the methyl ester can be converted into alternative C-terminal groups required for formulation or further synthetic elaboration. The conformationally biased Aib residue can be incorporated into larger peptide intermediates that serve as inputs for downstream coupling, deprotection, and final assembly steps in applied synthesis programs. The compound therefore serves as an amino acid-based intermediate that can be integrated into industrial synthetic routes for producing peptidomimetic and peptide-derived chemical entities.

5. Analytical Standards Development

H-Aib-OMe*HCl can be employed for analytical standards development and method qualification in contexts where Aib-containing amino acid derivatives or their peptide fragments are measured by chromatographic or mass spectrometric techniques. The defined stereochemistry at the α-carbon and the presence of an amino ester hydrochloride motif enable consistent reference preparation for quantitation of Aib-containing species, including monitoring of coupling completeness or tracking conversion between ester and acid forms. The methyl ester functionality supports preparation of defined derivatization states that can improve detectability or chromatographic behavior in analytical workflows. The product thus functions as a chemically characterized reference intermediate for amino acid and peptide analysis, supporting reliable interpretation of synthetic and quality-control data in biochemical research and industrial chemical manufacturing.

1. Crystal Structure of BamB from Pseudomonas aeruginosa and Functional Evaluation of Its Conserved Structural Features

2. Myotropic activity and immunolocalization of selected neuropeptides of the burying beetle Nicrophorus vespilloides (Coleoptera: Silphidae)

3. Glucagonlike peptide 2 analogue teduglutide: stimulation of proliferation but reduction of differentiation in human Caco-2 intestinal epithelial cells

4. Constitutive and inflammation-dependent antimicrobial peptides produced by epithelium are differentially processed and inactivated by the commensal Finegoldia magna and the pathogen Streptococcus pyogenes

5. Proinsulin C-peptide and insulin: Limited pattern similarities of interest in inter-peptide interactions but no C-peptide effect on insulin and IGF-1 receptor signaling